agio

(redirected from agios)
Also found in: Dictionary, Legal, Financial, Encyclopedia.
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for agio

a fee charged for exchanging currencies

References in periodicals archive ?
David Schenkein, chief executive officer at Agios, said, 'Through her tenure at Celgene we had the privilege of working with Jackie and seeing first-hand the value she brings to a growing biotechnology company, so we are thrilled to welcome her to the Agios board of directors.
This strategic agreement combines Agios scientific leadership in cellular metabolism with Celgenes expertise and growing efforts in immuno-oncology and builds upon the extremely productive partnership and working relationship that exist between our two companies.
This report provides comprehensive information on the current therapeutic developmental pipeline of Agios Pharmaceuticals, Inc.
In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class programs in cancer metabolism and inborn errors of metabolism advancing toward the clinic.
The tourists were on day trip to Spinalonga, a tiny islet some 15 miles north of Agios Nikolaos which was used as a leper colony early this century.
The exercise of the option to purchase additional shares brought the total number of shares of common stock sold by Agios to 3,876,403 shares
The new partnership deal sees Celgene paying $200 million upfront for opt-in development rights to early research Agios is implementing into new drug targets altering the metabolism of immune cells to help kill cancer cells.
Celgene will pay Agios USD200m upfront for an initial four-year research term, and holds an option to extend the collaboration for a further two years for an undisclosed amount.
These are the following working groups Group A: Supportive work Lignite Conveyor systems, Laboratory facilities and perform ancillary work in these areas of SES Agios Dimitrios.
Tumors carrying IDH mutations are known to produce high levels of 2-HG, as shown originally by Agios scientists in Nature in 2009.
M2 EQUITYBITES-March 26, 2015-US FDA grants orphan drug designation to Agios Pharmaceuticals' AG-348
M2 PHARMA-March 26, 2015-US FDA grants orphan drug designation to Agios Pharmaceuticals' AG-348
Agios Pharmaceuticals, the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that David Schenkein, M.
Novel drugs company Agios Pharmaceuticals (NasdaqGS:AGIO) reported on Monday that it has begun an underwritten public offering of 2,000,000 shares of its common stock.